{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=recombinant+viral+vaccine+therapy&page=5",
    "query": {
      "intervention": "recombinant viral vaccine therapy",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 190,
    "total_pages": 19,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=recombinant+viral+vaccine+therapy&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=recombinant+viral+vaccine+therapy&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T06:54:36.872Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01005407",
      "title": "Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "HEPLISAV and/or Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Engerix-B",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Dynavax Technologies Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "40 Years to 70 Years"
      },
      "enrollment_count": 2452,
      "start_date": "2010-02",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2019-03-20",
      "last_synced_at": "2026-10-14T06:54:36.872Z",
      "location_count": 29,
      "location_summary": "Huntsville, Alabama • San Diego, California • Santa Ana, California + 26 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01005407"
    },
    {
      "nct_id": "NCT01493154",
      "title": "Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "DNA Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 2,
      "start_date": "2012-04",
      "completion_date": "2015-10",
      "has_results": false,
      "last_update_posted_date": "2018-11-23",
      "last_synced_at": "2026-10-14T06:54:36.872Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01493154"
    },
    {
      "nct_id": "NCT05293665",
      "title": "Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19 Vaccines"
      ],
      "interventions": [
        {
          "name": "UB-612",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ChAdOx1-S vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sinopharm BIBP",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Vaxxinity, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 944,
      "start_date": "2022-03-16",
      "completion_date": "2023-09",
      "has_results": false,
      "last_update_posted_date": "2022-10-14",
      "last_synced_at": "2026-10-14T06:54:36.872Z",
      "location_count": 1,
      "location_summary": "Brownsville, Texas",
      "locations": [
        {
          "city": "Brownsville",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05293665"
    },
    {
      "nct_id": "NCT02285998",
      "title": "Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Flublok Quadrivalent Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Inactivated Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Protein Sciences Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 9003,
      "start_date": "2014-10",
      "completion_date": "2015-05",
      "has_results": true,
      "last_update_posted_date": "2017-10-27",
      "last_synced_at": "2026-10-14T06:54:36.872Z",
      "location_count": 38,
      "location_summary": "Mobile, Alabama • Tempe, Arizona • Little Rock, Arkansas + 34 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Redding",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02285998"
    },
    {
      "nct_id": "NCT03694392",
      "title": "Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Influenza",
        "Pneumonia",
        "Lower Respiratory Tract Infection",
        "Acute Myocardial Infarction",
        "Congestive Heart Failure",
        "Stroke"
      ],
      "interventions": [
        {
          "name": "Flublok Quadrivalent",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard Dose Inactivated Influenza Vaccine (SD-IIV)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Kaiser Permanente",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 2776278,
      "start_date": "2018-09-16",
      "completion_date": "2022-12-31",
      "has_results": true,
      "last_update_posted_date": "2025-04-08",
      "last_synced_at": "2026-10-14T06:54:36.872Z",
      "location_count": 1,
      "location_summary": "Oakland, California",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03694392"
    },
    {
      "nct_id": "NCT04469179",
      "title": "Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19",
        "SARS-CoV2"
      ],
      "interventions": [
        {
          "name": "SAB-185",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Normal Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "SAb Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 21,
      "start_date": "2020-08-20",
      "completion_date": "2021-11",
      "has_results": false,
      "last_update_posted_date": "2021-10-26",
      "last_synced_at": "2026-10-14T06:54:36.872Z",
      "location_count": 3,
      "location_summary": "Miami Beach, Florida • Omaha, Nebraska • Sioux Falls, South Dakota",
      "locations": [
        {
          "city": "Miami Beach",
          "state": "Florida"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Sioux Falls",
          "state": "South Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04469179"
    },
    {
      "nct_id": "NCT05329961",
      "title": "Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Human Papilloma Virus"
      ],
      "interventions": [
        {
          "name": "Gardasil9",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boston Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "8 Years",
        "sex": "ALL",
        "summary": "4 Years to 8 Years"
      },
      "enrollment_count": 155,
      "start_date": "2022-09-26",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-10-14T06:54:36.872Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05329961"
    },
    {
      "nct_id": "NCT04796896",
      "title": "A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "SARS-CoV-2"
      ],
      "interventions": [
        {
          "name": "mRNA-1273",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1273.214",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "6 Months to 11 Years"
      },
      "enrollment_count": 11942,
      "start_date": "2021-03-15",
      "completion_date": "2024-03-15",
      "has_results": true,
      "last_update_posted_date": "2025-06-13",
      "last_synced_at": "2026-10-14T06:54:36.872Z",
      "location_count": 83,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 68 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Banning",
          "state": "California"
        },
        {
          "city": "El Monte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04796896"
    },
    {
      "nct_id": "NCT04516746",
      "title": "Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19",
        "SARS-CoV-2"
      ],
      "interventions": [
        {
          "name": "AZD1222",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 32450,
      "start_date": "2020-08-28",
      "completion_date": "2023-02-10",
      "has_results": true,
      "last_update_posted_date": "2024-02-05",
      "last_synced_at": "2026-10-14T06:54:36.872Z",
      "location_count": 78,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 66 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "El Centro",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04516746"
    },
    {
      "nct_id": "NCT06605625",
      "title": "Vaccine Responses in Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Viral Vaccines"
      ],
      "interventions": [
        {
          "name": "Influenza vaccination",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Zoster Vaccine Recombinant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 250,
      "start_date": "2022-11-04",
      "completion_date": "2028-10",
      "has_results": false,
      "last_update_posted_date": "2025-10-28",
      "last_synced_at": "2026-10-14T06:54:36.872Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06605625"
    }
  ]
}